INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (12th June 2019) - Morschhauser, F.; Tilly, H.; Chaidos, A.; Phillips, T.; Ribrag, V.; Campbell, P.; Ghandi Laurent, D.; Jurczak, W.; McKay, P.; Opat, S.; Radford, J.; Rajarethinam, A.; et al.